

Xspray Pharma invites to Investor Update in Gothenburg

Xspray Pharma invites investors, shareholders and analysts to an Investor Update in Gothenburg on Friday, October 2, 2026. The event will be hosted by Xspray as a separate investor event at Gothia Towers, at the same time and venue as the ESH-iCMLf John Goldman Conference on Chronic Myeloid Leukemia.

The event will combine a strategy and company progress update by CEO Blake Leitch, new scientific posters explained by CSO and co-founder Per Andersson, and a moderated discussion with two internationally recognized CML experts: Michael J. Mauro, MD, and Jorge Cortes, MD. Both guest speakers are scientific advisors to Xspray and co-authors of Xspray poster abstracts being presented at the Goldman Conference.

The Investor Update will provide a broader view of Xspray's transition toward commercial oncology execution, including Dasynoc, Nilopki, launch readiness, the current regulatory situation and the market and future role of the HyNap platform. With new scientific data being presented during the Goldman Conference, the event will also give investors the opportunity to hear how leading US clinical CML-experts view the significance of improved targeted therapies in CML.

Date: Friday, October 2, 2026

Venue: Gothia Towers, Gothenburg or participate live online

Presentation: 12:30–14:00 CEST

Light lunch and registration for participants on site from 11:45 CEST

[Please register here](#)

When you register, you can choose if you would like to participate on-site or online.

A link will be sent out in advance to registered online participants.

“The Goldman Conference provides a highly relevant scientific setting for a broader Xspray investor update. We look forward to discussing our progress, our commercial priorities and the continued development of Dasynoc, while also providing scientific context from new data being presented during the conference,” says Blake Leitch, CEO of Xspray Pharma.

For further information, please contact:

Jacob Nyberg, IRO

Xspray Pharma AB (publ)

Tel: + 46 (0) 70 767 08 83

E-mail: ir@xspray.com

About Xspray Pharma

Xspray Pharma AB (publ) is a pharmaceutical company with several product candidates in clinical development utilizing its innovative, patent protected HyNap™ technology platform to create improved versions of marketed protein kinase inhibitors (PKI), the largest oncology market segment, often with high drug prices. The company's goal is to become the market leader in improved PKI's for cancer treatment. Xspray Pharma's lead drug candidate, Dasynoc® and Nilopki® (an optimized version of Tasigna®) are currently undergoing FDA review. Dasynoc is an amorphous form of dasatinib, demonstrating bioequivalence at a 30% lower dose due to a better solubility profile. Its compatibility with proton pump inhibitors (PPIs), which are often co-prescribed to patients with CML and ALL, is a significant advantage. Xspray Pharma is building a robust product portfolio, including Nilopki and XS008-axitinib (an optimized version of Inlyta®) and XS025-cabozantinib (an optimized version of Cabometyx®).

The Xspray Pharma AB-share is trading at Nasdaq Stockholm (Nasdaq Stockholm: XSPRAY).
www.xspraypharma.com.

Attachments

[Xspray Pharma invites to Investor Update in Gothenburg](#)